London-based Lexicon Bio secures £375k to advance programmable transcriptional editing

Programmable transcriptional editing using small molecules is the focus of Lexicon Bio, a London-based biotechnology firm that has recently secured £375k in new funding. This capital injection values the company at an estimated £4m.

Incorporated in July 2025, Lexicon Bio operates a discovery engine designed to combine modular library synthesis with full transcriptome profiling for every compound. This approach generates functional data at a scale and resolution intended to surpass conventional screening methods. The platform is built to identify hits, clarify biological mechanisms, and de-risk experimental biology simultaneously.

The company focuses on research and experimental development within biotechnology, specifically targeting biology research, bioinformatics, and cell and tissue culture. Its technical scope includes DNA and RNA research, the study of gene and RNA vectors, nanobiotechnology, and process biotechnology techniques involving proteins and other molecules.

Lexicon Bio currently manages active programmes in oncology, regenerative medicine, and immunology. The firm has already identified lead chemical matter across multiple transcription factor targets.

This funding round follows the company's formation less than a year ago. Documentation filed in April (with an allotment date in March) indicates the £375k investment. LinkedIn data currently lists the company as having zero employees, reflecting its early-stage status. The firm is headquartered in London and maintains a focus on biotechnology research through its proprietary discovery platform.